Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Celgene International has reported that clinical data from the Eastern Cooperative Oncology Group's large, randomized Phase III trial evaluating oral Revlimid with low-dose dexamethasone continued to demonstrate superior overall survival rates for newly diagnosed multiple myeloma patients compared to Revlimid with the standard high-dose dexamethasone.
Subscribe to our email newsletter
Revlimid was active with both dose levels of dexamethasone. The best overall response for high-dose dexamethasone (CR/VGPR/PR) was 82% compared to 71% in the low-dose dexamethasone arm, including 52% and 42% CR/VGPR. After a median 21 months follow-up, the median duration of response has not been met in either arm. While the low-dose arm had lower response rates, it was associated with superior overall survival. Additionally, time to disease progression and progression-free survival were similar in both arms of the study.
The 87% survival rate in the arm with Revlimid and low-dose dexamethasone at two years showed an advantage compared to the two-year survival rate of 75% for patients who received Revlimid and high-dose dexamethasone. Increased overall survival was seen in patients receiving Revlimid and low-dose dexamethasone regardless of age; however, patients under the age of 65 showed a two-year survival probability of 91% compared to 85% using high-dose dexamethasone at two years.
In patients who continued on treatment past six months, the 99% survival rate showed an advantage compared to a survival rate of 97% for patients who received Revlimid and high-dose dexamethasone at one year.